SCHEMBL3758362

SCHEMBL3758362

FC(F)(F)c1cc(Br)cc(N2CCOCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.49
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 4/20 0.45
LMNA P02545 3/20 0.45
PHGDH O43175 1/20 0.44
AKR1C3 P42330 1/20 0.43
MAPT P10636 4/20 0.41
TSHR P16473 2/20 0.41
NR4A1 P22736 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TLR9 Q9NR96 1/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
GAA P10253 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12684724 0.84 ADRB1 (0.53) ADRB1ALDH1A1LMNAPHGDHMAPT
SCHEMBL24270121 0.82 KDM4E (0.50) KDM4EALDH1A1LMNAAKR1C3MAPT
SCHEMBL29715891 0.80 KDM4E (0.53) ADRB1KDM4EALDH1A1LMNAAKR1C3
SCHEMBL5340202 0.80 ADRB1 (0.77) ADRB1ALDH1A1PHGDHMAPTSMN1; SMN2
SCHEMBL14092965 0.80 ADRB1 (0.53) ADRB1KDM4EALDH1A1LMNAAKR1C3
SCHEMBL10104265 0.80 LMNA (0.49) ADRB1KDM4EALDH1A1LMNAPHGDH
SCHEMBL1928369 0.80 KDM4E (0.53) ADRB1KDM4EALDH1A1LMNAAKR1C3
SCHEMBL18277904 0.80 PHGDH (0.49) ADRB1ALDH1A1PHGDHMAPTHTR3E
SCHEMBL20556720 0.80 ADRB1 (0.45) ADRB1KDM4EALDH1A1LMNAAKR1C3
Piperazine SCHEMBL23217140 0.79 ADRB1 (0.75) ADRB1ALDH1A1PHGDHMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150232429-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE 2015-08-20 US disclosed
US-9018205-B2 Substituted pyrimidinyl-amines as protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2015-04-28 US disclosed
EP-2200436-B1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS SCRIPPS RESEARCH INST (US) 2015-01-21 EP disclosed
US-8530480-B2 Substituted pyrimidinyl-amines as protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2013-09-10 US disclosed
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2013-09-05 US disclosed
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
EP-2200436-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS The Scripps Research Institute (US) 2010-06-30 EP disclosed
WO-2009032861-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 ADRB1 2017/4885KDM4E 2345/4885ALDH1A1 4097/4885
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 ADRB1 2017/4885KDM4E 2345/4885ALDH1A1 4097/4885
US-20150232429-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 ADRB1 2017/4885KDM4E 2345/4885ALDH1A1 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.